Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer

Sandeep Shelar, Eun Hee Shim, Garrett J. Brinkley, Anirban Kundu, Francesca Carobbio, Tyler Poston, Jubilee Tan, Vishwas Parekh, Daniel Benson, David K. Crossman, Phillip J. Buckhaults, Dinesh Rakheja, Richard Kirkman, Yusuke Sato, Seishi Ogawa, Shilpa Dutta, Sadanandan E. Velu, Ethan Emberley, Alison Pan, Jason ChenTony Huang, Devin Absher, Anja Becker, Conrad Kunick, Sunil Sudarshan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Elevation of L-2-hydroxylgutarate (L-2-HG) in renal cell carcinoma (RCC) is due in part to reduced expression of L-2-HG dehydrogenase (L2HGDH). However, the contribution of L-2-HG to renal carcinogenesis and insight into the biochemistry and targets of this small molecule remains to be elucidated. Experimental Design: Genetic and pharmacologic approaches to modulate L-2-HG levels were assessed for effects on in vitro and in vivo phenotypes. Metabolomics was used to dissect the biochemical mechanisms that promote L-2-HG accumulation in RCC cells. Transcriptomic analysis was utilized to identify relevant targets of L-2-HG. Finally, bioinformatic and metabolomic analyses were used to assess the L-2-HG/L2HGDH axis as a function of patient outcome and cancer progression. Results: L2HGDH suppresses both in vitro cell migration and in vivo tumor growth and these effects are mediated by L2HGDH's catalytic activity. Biochemical studies indicate that glutamine is the predominant carbon source for L-2-HG via the activity of malate dehydrogenase 2 (MDH2). Inhibition of the glutamine-MDH2 axis suppresses in vitro phenotypes in an L-2-HG–dependent manner. Moreover, in vivo growth of RCC cells with basal elevation of L-2-HG is suppressed by glutaminase inhibition. Transcriptomic and functional analyses demonstrate that the histone demethylase KDM6A is a target of L-2-HG in RCC. Finally, increased L-2-HG levels, L2HGDH copy loss, and lower L2HGDH expression are associated with tumor progression and/or worsened prognosis in patients with RCC. Conclusions: Collectively, our studies provide biochemical and mechanistic insight into the biology of this small molecule and provide new opportunities for treating L-2-HG–driven kidney cancers.

Original languageEnglish (US)
Pages (from-to)6433-6446
Number of pages14
JournalClinical Cancer Research
Volume24
Issue number24
DOIs
StatePublished - Dec 15 2018

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Epigenomics
Oxidoreductases
Malate Dehydrogenase
Metabolomics
Glutamine
Histone Demethylases
Glutaminase
Phenotype
Therapeutics
Neoplasms
Growth
Computational Biology
Biochemistry
Cell Movement
Carcinogenesis
Research Design
Carbon
alpha-hydroxyglutarate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Shelar, S., Shim, E. H., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T., ... Sudarshan, S. (2018). Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer. Clinical Cancer Research, 24(24), 6433-6446. https://doi.org/10.1158/1078-0432.CCR-18-1727

Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer. / Shelar, Sandeep; Shim, Eun Hee; Brinkley, Garrett J.; Kundu, Anirban; Carobbio, Francesca; Poston, Tyler; Tan, Jubilee; Parekh, Vishwas; Benson, Daniel; Crossman, David K.; Buckhaults, Phillip J.; Rakheja, Dinesh; Kirkman, Richard; Sato, Yusuke; Ogawa, Seishi; Dutta, Shilpa; Velu, Sadanandan E.; Emberley, Ethan; Pan, Alison; Chen, Jason; Huang, Tony; Absher, Devin; Becker, Anja; Kunick, Conrad; Sudarshan, Sunil.

In: Clinical Cancer Research, Vol. 24, No. 24, 15.12.2018, p. 6433-6446.

Research output: Contribution to journalArticle

Shelar, S, Shim, EH, Brinkley, GJ, Kundu, A, Carobbio, F, Poston, T, Tan, J, Parekh, V, Benson, D, Crossman, DK, Buckhaults, PJ, Rakheja, D, Kirkman, R, Sato, Y, Ogawa, S, Dutta, S, Velu, SE, Emberley, E, Pan, A, Chen, J, Huang, T, Absher, D, Becker, A, Kunick, C & Sudarshan, S 2018, 'Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer', Clinical Cancer Research, vol. 24, no. 24, pp. 6433-6446. https://doi.org/10.1158/1078-0432.CCR-18-1727
Shelar, Sandeep ; Shim, Eun Hee ; Brinkley, Garrett J. ; Kundu, Anirban ; Carobbio, Francesca ; Poston, Tyler ; Tan, Jubilee ; Parekh, Vishwas ; Benson, Daniel ; Crossman, David K. ; Buckhaults, Phillip J. ; Rakheja, Dinesh ; Kirkman, Richard ; Sato, Yusuke ; Ogawa, Seishi ; Dutta, Shilpa ; Velu, Sadanandan E. ; Emberley, Ethan ; Pan, Alison ; Chen, Jason ; Huang, Tony ; Absher, Devin ; Becker, Anja ; Kunick, Conrad ; Sudarshan, Sunil. / Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 24. pp. 6433-6446.
@article{ae6d4b7a6d4f466d8785046e64142378,
title = "Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer",
abstract = "Purpose: Elevation of L-2-hydroxylgutarate (L-2-HG) in renal cell carcinoma (RCC) is due in part to reduced expression of L-2-HG dehydrogenase (L2HGDH). However, the contribution of L-2-HG to renal carcinogenesis and insight into the biochemistry and targets of this small molecule remains to be elucidated. Experimental Design: Genetic and pharmacologic approaches to modulate L-2-HG levels were assessed for effects on in vitro and in vivo phenotypes. Metabolomics was used to dissect the biochemical mechanisms that promote L-2-HG accumulation in RCC cells. Transcriptomic analysis was utilized to identify relevant targets of L-2-HG. Finally, bioinformatic and metabolomic analyses were used to assess the L-2-HG/L2HGDH axis as a function of patient outcome and cancer progression. Results: L2HGDH suppresses both in vitro cell migration and in vivo tumor growth and these effects are mediated by L2HGDH's catalytic activity. Biochemical studies indicate that glutamine is the predominant carbon source for L-2-HG via the activity of malate dehydrogenase 2 (MDH2). Inhibition of the glutamine-MDH2 axis suppresses in vitro phenotypes in an L-2-HG–dependent manner. Moreover, in vivo growth of RCC cells with basal elevation of L-2-HG is suppressed by glutaminase inhibition. Transcriptomic and functional analyses demonstrate that the histone demethylase KDM6A is a target of L-2-HG in RCC. Finally, increased L-2-HG levels, L2HGDH copy loss, and lower L2HGDH expression are associated with tumor progression and/or worsened prognosis in patients with RCC. Conclusions: Collectively, our studies provide biochemical and mechanistic insight into the biology of this small molecule and provide new opportunities for treating L-2-HG–driven kidney cancers.",
author = "Sandeep Shelar and Shim, {Eun Hee} and Brinkley, {Garrett J.} and Anirban Kundu and Francesca Carobbio and Tyler Poston and Jubilee Tan and Vishwas Parekh and Daniel Benson and Crossman, {David K.} and Buckhaults, {Phillip J.} and Dinesh Rakheja and Richard Kirkman and Yusuke Sato and Seishi Ogawa and Shilpa Dutta and Velu, {Sadanandan E.} and Ethan Emberley and Alison Pan and Jason Chen and Tony Huang and Devin Absher and Anja Becker and Conrad Kunick and Sunil Sudarshan",
year = "2018",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-18-1727",
language = "English (US)",
volume = "24",
pages = "6433--6446",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer

AU - Shelar, Sandeep

AU - Shim, Eun Hee

AU - Brinkley, Garrett J.

AU - Kundu, Anirban

AU - Carobbio, Francesca

AU - Poston, Tyler

AU - Tan, Jubilee

AU - Parekh, Vishwas

AU - Benson, Daniel

AU - Crossman, David K.

AU - Buckhaults, Phillip J.

AU - Rakheja, Dinesh

AU - Kirkman, Richard

AU - Sato, Yusuke

AU - Ogawa, Seishi

AU - Dutta, Shilpa

AU - Velu, Sadanandan E.

AU - Emberley, Ethan

AU - Pan, Alison

AU - Chen, Jason

AU - Huang, Tony

AU - Absher, Devin

AU - Becker, Anja

AU - Kunick, Conrad

AU - Sudarshan, Sunil

PY - 2018/12/15

Y1 - 2018/12/15

N2 - Purpose: Elevation of L-2-hydroxylgutarate (L-2-HG) in renal cell carcinoma (RCC) is due in part to reduced expression of L-2-HG dehydrogenase (L2HGDH). However, the contribution of L-2-HG to renal carcinogenesis and insight into the biochemistry and targets of this small molecule remains to be elucidated. Experimental Design: Genetic and pharmacologic approaches to modulate L-2-HG levels were assessed for effects on in vitro and in vivo phenotypes. Metabolomics was used to dissect the biochemical mechanisms that promote L-2-HG accumulation in RCC cells. Transcriptomic analysis was utilized to identify relevant targets of L-2-HG. Finally, bioinformatic and metabolomic analyses were used to assess the L-2-HG/L2HGDH axis as a function of patient outcome and cancer progression. Results: L2HGDH suppresses both in vitro cell migration and in vivo tumor growth and these effects are mediated by L2HGDH's catalytic activity. Biochemical studies indicate that glutamine is the predominant carbon source for L-2-HG via the activity of malate dehydrogenase 2 (MDH2). Inhibition of the glutamine-MDH2 axis suppresses in vitro phenotypes in an L-2-HG–dependent manner. Moreover, in vivo growth of RCC cells with basal elevation of L-2-HG is suppressed by glutaminase inhibition. Transcriptomic and functional analyses demonstrate that the histone demethylase KDM6A is a target of L-2-HG in RCC. Finally, increased L-2-HG levels, L2HGDH copy loss, and lower L2HGDH expression are associated with tumor progression and/or worsened prognosis in patients with RCC. Conclusions: Collectively, our studies provide biochemical and mechanistic insight into the biology of this small molecule and provide new opportunities for treating L-2-HG–driven kidney cancers.

AB - Purpose: Elevation of L-2-hydroxylgutarate (L-2-HG) in renal cell carcinoma (RCC) is due in part to reduced expression of L-2-HG dehydrogenase (L2HGDH). However, the contribution of L-2-HG to renal carcinogenesis and insight into the biochemistry and targets of this small molecule remains to be elucidated. Experimental Design: Genetic and pharmacologic approaches to modulate L-2-HG levels were assessed for effects on in vitro and in vivo phenotypes. Metabolomics was used to dissect the biochemical mechanisms that promote L-2-HG accumulation in RCC cells. Transcriptomic analysis was utilized to identify relevant targets of L-2-HG. Finally, bioinformatic and metabolomic analyses were used to assess the L-2-HG/L2HGDH axis as a function of patient outcome and cancer progression. Results: L2HGDH suppresses both in vitro cell migration and in vivo tumor growth and these effects are mediated by L2HGDH's catalytic activity. Biochemical studies indicate that glutamine is the predominant carbon source for L-2-HG via the activity of malate dehydrogenase 2 (MDH2). Inhibition of the glutamine-MDH2 axis suppresses in vitro phenotypes in an L-2-HG–dependent manner. Moreover, in vivo growth of RCC cells with basal elevation of L-2-HG is suppressed by glutaminase inhibition. Transcriptomic and functional analyses demonstrate that the histone demethylase KDM6A is a target of L-2-HG in RCC. Finally, increased L-2-HG levels, L2HGDH copy loss, and lower L2HGDH expression are associated with tumor progression and/or worsened prognosis in patients with RCC. Conclusions: Collectively, our studies provide biochemical and mechanistic insight into the biology of this small molecule and provide new opportunities for treating L-2-HG–driven kidney cancers.

UR - http://www.scopus.com/inward/record.url?scp=85053293823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053293823&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1727

DO - 10.1158/1078-0432.CCR-18-1727

M3 - Article

C2 - 30108105

AN - SCOPUS:85053293823

VL - 24

SP - 6433

EP - 6446

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -